Gosset Ownership
Private
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Blackrock Neurotech General Information
Blackrock Neurotech’s brain-computer interface technologies have enabled patients with paralysis to control computers, robotic arms, communicate via email or text by thought alone, and regain some independence. Their Utah Array has been implanted in over 30 people as part of clinical studies to restore movement or communication. The MoveAgain BCI is their first device designed specifically for clinical use and is progressing toward broader patient access. No large-scale pivotal trial results published yet.
Contact Information
Drug Pipeline
MoveAgain
CommercialKey Partnerships
Cognixion (distribution partnership on non-invasive Axon-R platform)
Blackrock Neurotech Funding
No funding data available
To view Blackrock Neurotech's complete valuation and funding history, request access »